No Data
No Data
Annovis Bio Granted U.S. Patent For Buntanetap In Treating Acute Neurodegenerative Injuries; Global Protection Secured
Maxim Group Maintains Annovis Bio(ANVS.US) With Buy Rating, Maintains Target Price $25
Annovis Bio: Strategic Advancements and Phase 3 Trial Acceleration Justify Buy Rating
Annovis Bio Says FDA Approved Revised Protocol for Phase 3 Alzheimer's Disease Study
Annovis Bio Announces The FDA Has Accepted An Updated Protocol For Its Phase 3 Alzheimer's Disease Study
Express News | Annovis Bio Inc - Revised Protocol Includes 6-Month Symptomatic and 12-Month Disease-Modifying Assessment